Overlap Syndrome of Myocarditis–Myositis– Myasthenia Induced by Immunotherapy in Advanced Melanoma: A Case Report
Open Access
- 3 June 2026
- journal article
- Published by AMO Publisher in European Journal of Medical and Health Research
- Vol. 4 (4) , 72-75
Abstract
Immune checkpoint inhibitors have transformed the treatment of advanced melanoma; however, they may be associated with potentially severe immune-related adverse events. Among these, myocarditis–myositis– myasthenia overlap syndrome (MMM) is a rare but highly life-threatening condition. We report the case of an 84-year-old patient with stage IV melanoma treated with nivolumab and ipilimumab using a reduced-dose regimen, who initially developed immune-mediated hepatitis, followed by proximal muscle weakness, bulbar involvement, and myasthenic symptoms, associated with markedly elevated creatine kinase levels. During hospitalization, the patient developed complete atrioventricular block and significant troponin elevation, consistent with MMM overlap syndrome. Treatment with high-dose intravenous methylprednisolone followed by oral corticosteroids and pyridostigmine was initiated, resulting in favorable clinical evolution, with neurological improvement and hemodynamic stabilization without the need for second-line therapies. This case highlights the importance of early recognition of severe immune- related adverse events, the need for a multidisciplinary approach, and prompt initiation of immunosuppressive therapy, which may significantly improve clinical outcomes even in elderly patients.Keywords
This publication has 21 references indexed in Scilit:
- Nivolumab- and ipilimumab-induced myositis, myasthenia gravis, and myocarditis in a patient with metastatic melanomaAnti-Cancer Drugs, 2025
- Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected MelanomaJAMA Network Open, 2023
- Advances and ongoing research in the treatment of autoimmune neuromuscular junction disordersThe Lancet Neurology, 2022
- Immune-Related Adverse Events Associated with Immune Checkpoint BlockadeNew England Journal of Medicine, 2018
- Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancerMedicine, 2017
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Myasthenia gravis: subgroup classification and therapeutic strategiesThe Lancet Neurology, 2015
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002